Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics
April 17 (Reuters) - Channel Therapeutics Corp CHRO.A:
LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL THERAPEUTICS
CHANNEL THERAPEUTICS CORP - PROPOSED TRANSACTION WILL RAISE $50 MILLION IN EQUITY CAPITAL
CHANNEL THERAPEUTICS CORP - LIGAND IS ENTITLED TO A 13% ROYALTY ON WORLDWIDE SALES OF ZELSUVMI
CHANNEL THERAPEUTICS CORP -COMBINED CO TO OPERATE UNDER NAME PELTHOS THERAPEUTICS INC., TRADE ON NYSE AMERICAN EXCHANGE UNDER TICKER PTHS
CHANNEL THERAPEUTICS CORP - UPON COMPLETION OF DEAL, PLESHA TO BECOME CEO OF COMBINED CO AND KNUETTEL TO BECOME CFO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








